In prostate cancer, FGFR1 and FGFR4 as well as the ligands FGF-1, FGF-2, FGF-6, FGF-8, FGF-9, and FGF-17 are all known to be over-expressed [4,27-31]. This evidence concerns the gene FGFR4 and prostate carcinoma.